AI assistant
Tonix Pharmaceuticals Holding Corp. — Director's Dealing 2016
Feb 29, 2016
33543_dirs_2016-02-29_5936e109-c784-4fa4-9caa-066c98eb3534.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK: 0001430306
Period of Report: 2016-02-24
Reporting Person: SAENGER BRADLEY (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.001 par value per share | 4039 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $9.87 | 2024-06-17 | Common Stock (11000) | Direct | |
| Stock Option | $6.68 | 2024-10-29 | Common Stock (11000) | Direct | |
| Stock Option | $5.95 | 2025-02-25 | Common Stock (13000) | Direct | |
| Stock Option | $5.03 | 2027-02-09 | Common Stock (15000) | Direct |
Footnotes
F1: The option was granted on June 17, 2014 pursuant to the Issuer's 2014 Stock Incentive Plan. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2: The option was granted on October 29, 2014 pursuant to the Issuer's 2014 Stock Incentive Plan. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F3: The option was granted on February 25, 2015 pursuant to the Issuer's 2014 Stock Incentive Plan. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F4: The option was granted on February 9, 2016 pursuant to the Issuer's 2014 Stock Incentive Plan. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.